Merck & Co. secured FDA approval for Keytruda Qlex, a subcutaneous injection formulation of its blockbuster anti-PD-1 cancer immunotherapy. This SC version can be administered in about one minute, compared to the original 30-minute intravenous infusion, providing convenience for patients and healthcare providers. Clinical trial data demonstrated that the injectable Keytruda formulation offers comparable efficacy and safety profiles to the intravenous form. This approval marks the first subcutaneous immune checkpoint inhibitor on the market and may enhance patient throughput and compliance for various solid tumors treated with Keytruda.